Cubist Systematic Strategies LLC Buys Shares of 26,121 Candel Therapeutics, Inc. (NASDAQ:CADL)

Cubist Systematic Strategies LLC purchased a new position in Candel Therapeutics, Inc. (NASDAQ:CADL) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 26,121 shares of the company’s stock, valued at approximately $162,000. Cubist Systematic Strategies LLC owned approximately 0.09% of Candel Therapeutics at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp purchased a new position in Candel Therapeutics in the second quarter valued at about $338,000. Rhumbline Advisers acquired a new position in shares of Candel Therapeutics during the 2nd quarter worth $143,000. Finally, Point72 DIFC Ltd bought a new position in shares of Candel Therapeutics during the 2nd quarter valued at $31,000. 13.93% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Candel Therapeutics

In related news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the sale, the insider now owns 929,873 shares in the company, valued at approximately $5,597,835.46. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 31,800 shares of company stock worth $193,380. Insiders own 41.60% of the company’s stock.

Candel Therapeutics Price Performance

Shares of NASDAQ:CADL opened at $5.95 on Wednesday. The business has a 50-day moving average of $6.31 and a two-hundred day moving average of $6.81. Candel Therapeutics, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $14.30. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.62 and a quick ratio of 1.62. The stock has a market capitalization of $177.05 million, a P/E ratio of -4.65 and a beta of -0.95.

Candel Therapeutics (NASDAQ:CADL) last released its earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. On average, equities research analysts predict that Candel Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Candel Therapeutics Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.